Table 3.

Urine Cr-normalized biomarker levels in a primary validation cohort.

Urine protein	Fold-changea
	Active/inactive	SLE/healthy	Comparison of active LN vs inactive SLE
			Cut-off	ROC AUC	Sensitivity	Specificity	NPV	PPV
ALCAM	3.0***	40.7****	4875	0.74***	0.52	0.92	0.78	0.77
BFL-1	3.3***	4.3	11	0.74****	0.70	0.81	0.68	0.83
Calpastatin	63**	51.0*	325	0.74****	0.52	0.98	0.93	0.78
FcγRIIBC	3.2*	2.7	367	0.69**	0.59	0.79	0.62	0.77
Hemopexin	1.5***	2.8	327459	0.76****	0.96	0.57	0.57	0.96
MCP-1	2.9**	4.4**	203	0.71***	0.78	0.62	0.54	0.83
Peroxiredoxin-6	7.2	2.8	1	0.58	0.30	0.87	0.57	0.68
PF-4	8.9****	84.7**	39	0.81****	0.78	0.83	0.72	0.87
Properdin	6.2**	6.2	2062	0.79****	0.74	0.89	0.80	0.86
sE-Selectin	2.6**	22.2*	3	0.73****	0.82	0.66	0.58	0.86
TFPI	1.9	6.3****	146	0.65*	0.63	0.75	0.59	0.78
VCAM-1	2.5****	0.2	10324	0.85****	0.82	0.79	0.69	0.88
C3	0.9	N/A	146	0.39	0.19	0.92	0.56	0.66
C4	1	N/A	30	0.49	0.33	0.81	0.50	0.68
Anti-DNA	3.7	N/A	40	0.66**	0.52	0.81	0.61	0.75

The primary validation cohort of 95 subjects comprise 47 inactive SLE patients,

27 active LN patients, and 21 healthy controls.

Source data are provided as a Source Data file.

^ap-values by Mann–Whitney U-test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).